



Safe surgery for  
multiple breast cancers

## Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence?

(MIAMI feasibility RCT)

### RECENT NEWS

- ▶ NIHR Research for Patient Benefit Funding in November 2016 for the feasibility phase randomised trial, which will be the first multicentre RCT of multiple Ipsilateral breast cancers (MIBC)
- ▶ 5-7 UK centres participating in the feasibility study

### RANDOMIZATION DESIGN

Women will be randomly allocated in a 1:1 ratio between two arms:

#### Intervention

Multiple lumpectomies and Therapeutic Reduction Mammoplasty (Oncoplastic OBCS)

#### Standard

Mastectomy (+/- reconstruction)

All women will have molecular genotyping of each cancer to support the choice of chemotherapy, endocrine treatment, anti-HER-2 therapy and/or radiotherapy as part of standard care. Standard care currently comprises whole breast radiotherapy after all BCS, and clinician-selected addition of either one or two "disease site" radiotherapy boosts, mostly in women <50 years of age, with clinician-selected chest wall radiotherapy after mastectomy (30-40%).


#### Feasibility Trial Outcomes

These include data needed to plan the main trial accurately, ascertaining rates, compliance and outcome measures.

#### Main trial primary outcome

5-year local recurrence in chest wall, retained skin or breast tissue, which is the outcome that mastectomy is designed to prevent.

### MIAMI FLOW DIAGRAM



### TRIAL STATUS

To start in June 2017.

5-15 patients per centre over 15 months.

For further information please contact the MIAMI trial email [SITU.MIAMI@ucl.ac.uk](mailto:SITU.MIAMI@ucl.ac.uk)

**Team:** UCL Surgical & Interventional Trials Unit (SITU), Dr. Norman Williams  
**Tel:** 0207 6799280

**Chief Investigator:** Miss Zoe Ellen Winters  
[z.winters@ucl.ac.uk](mailto:z.winters@ucl.ac.uk)

**Trials Office:** UCL SITU

**Sponsor:** UCL